Community herbal monograph on Capsella bursa-pastoris (L.) Medikus, herba

Similar documents
Community herbal monograph on Commiphora molmol Engler, gummi-resina

Community herbal monograph on Cucurbita pepo L., semen

Community herbal monograph on Arnica montana L., flos

Community herbal monograph on Panax ginseng C.A. Meyer, radix

Community herbal monograph on Lavandula angustifolia Miller, aetheroleum

Community herbal monograph on Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos

Community herbal monograph on Panax ginseng C.A.Meyer, radix

Community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum

Community herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium

European Union herbal monograph on Salvia officinalis L., folium

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS

European Union herbal monograph on Carum carvi L., aetheroleum

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE)

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (WELL-ESTABLISHED MEDICINAL USE)

NEUROTONE THR 00904/0005 UKPAR

Activities. but I will require that groups present research papers

UKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3

European Union herbal monograph on Ginkgo biloba L., folium

Community herbal monograph on Ginkgo biloba L., folium

GUIDELINES FOR TRANSLATING THE EUROPASS CERTIFICATE SUPPLEMENT INTRODUCTION GENERAL RECOMMENDATIONS

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

CMD(v)/GUI/014. GUIDANCE for The Processing of Generic Applications Through MRP / DCP

Guideline on stability testing for applications for variations to a marketing authorisation

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;

Arnicare Arnica 30c pillules NR 01175/0181 UKPAR

Kalms Tablets THR 01074/0235 UKPAR

Ginkgoforce Ginkgo biloba tablets THR 13668/0016 UKPAR

Questions and answers on post approval change management protocols

Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665

GUIDANCE for Administration of the Sunset Clause

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands

QRD recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products

SUMMARY OF PRODUCT CHARACTERISTICS

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

College ter Beoordeling van Geneesmiddelen (CBG) Medicines Evaluation Board (MEB) Graadt van Roggenweg AH Utrecht The Netherlands

Opinion/ Commission. Notification. Decision. Issued 2 / affected 3 amended on. 30/07/2015 Annex II, Labelling and PL

Stress Relief Daytime Valerian-Hops oral drops THR 13668/0027 UKPAR

European Medicines Agency decision

Urostemol Men capsules THR 02855/0240

Reflection paper on clinical aspects related to tissue engineered products

Questions and answers on post approval change management protocols

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ALOE BARBADENSIS MILLER

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

Adoption by CHMP for release for consultation November End of consultation (deadline for comments) 31 March 2011

Summary of Product Characteristics Medical Air

Decentralised Procedure. Public Assessment Report. Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC

Dormeasan Sleep Valerian-Hops oral drops THR 13668/0017 UKPAR

EU Clinical Trials Register. An agency of the European Union

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/CT 1. Revision 1

Public Assessment Report Scientific discussion. Tenofovir disoproxil Teva (tenofovir disoproxil) SE/H/1432/01/DC

Summary of Product Characteristics Medical Helium

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

MM, EFES EN. Marc Mathieu

SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product)

Montelukast 10mg film-coated tablets PL 17907/0474

ZOVIRAX Cold Sore Cream

Public Assessment Report. UK National Procedure. Perindopril 2 mg Tablets. Perindopril 4 mg Tablets. Perindopril 8 mg Tablets PL 20075/

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.

Official name: Department of Contracts National ID: Postal address: Notre Dame Ravelin Town: Floriana Postal code: FRN 1600

Draft Agreed by Pharmacokinetics Working Party January End of consultation (deadline for comments) 31 May 2011

Data submission of authorised medicines in the European Union

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

PL 17871/0208 UKPAR TABLE OF CONTENTS

EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - SEVERE AND SERIOUS HEPATIC REACTIONS -

1/ 9 TED19_NRI 13/03/2016- ID: Standard form 2 - EN PSNI - Supply of Pyrotechnics

General Principles for the Safety Assessment of Excipients

Questions and answers on preparation, management and assessment of periodic safety update reports (PSURs)

1/ 10 TED19_NRI 14/04/2016- ID: Standard form 2 - EN RI DEL-DELIVERY OF THE WORKABLE (NI) PROGRAMME

Guideline on Process Validation

1/ 9 TED19_MLT 23/10/2015- ID: Standard form 2 - EN Tender for the Supply of Consumables for A) Microware Generator and B) Rf Generator

1/ 8 TED19_SCC 27/05/2016- ID: Standard form 2 - EN Social Care Case Management System and Associated Modules

SURVEY ON THE TRAINING OF GENERAL CARE NURSES IN THE EUROPEAN UNION. The current minimum training requirements for general care nurses

IMPURITIES IN NEW DRUG PRODUCTS

Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials

CONTRACT NOTICE - ABOVE THRESHOLD SECTION I: CONTRACTING AUTHORITY I.1) NAME, ADDRESSES AND CONTACT POINT(S)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291

CORE SmPC FOR RADIOPHARMACEUTICALS

Westminster City Council c/o Enterprise FM Enterprise FM 33 Tachbrook Street Town: London Postal code: SWIV 2JR. Telephone:

Phynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies

Public Assessment Report. Decentralised Procedure

Draft agreed by Pharmacokinetics Working Party January Adoption by CHMP for release for consultation 17 February 2011

HYDROCORTISONE 10 MG TABLETS

Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules

Summary of Product Characteristics

Questions and answers on serious non-fatal adverse events and reporting rules

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130

Work instructions. 1. Changes since last revision. 2. Records. 3. Instructions EXPLANATORY NOTES

European Medicines Agency recommends restricting use of trimetazidine-containing medicines

The Legal Service of the European Commission. March

Medical Gas Data Sheet (MGDS) Medical air

CrossLoop Help. What would you like to do? Joining A Session

OFFICE FOR HARMONIZATION IN THE INTERNAL MARKET (TRADE MARKS AND DESIGNS) Certificate of Registration 1

SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

12 July 2011 EMA/HMPC/262766/2010 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Capsella bursa-pastoris (L.) Medikus, herba Final Discussion in Working Party on Community monographs and Community list (MLWP) May 2010 September 2020 November 2010 Adoption by Committee on Herbal Medicinal Products (HMPC) for release 25 November 2010 for consultation End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu 15 April 2011 Rediscussion in Working Party on Community monographs and Community list (MLWP) May 2011 Adoption by Committee on Herbal Medicinal Products (HMPC) 12 July 2011 Keywords Herbal medicinal products; HMPC; Community herbal monographs; traditional use; Capsella bursa-pastoris (L.) Medikus, herba; Bursae pastoris herba; shepherd s purse. BG (bălgarski): Овчарска торбичка, стрък CS (čeština): Nať pastuší tobolky DA (dansk): Hyrdetaske DE (Deutsch): Hirtentäschelkraut EL (elliniká): EN (English): Shepherd s purse ES (espanol): Bolsa de pastor, partes aéreas de ET (eesti keel): Hiirekõrvaürt FI (suomi): FR (français): Bourse à pasteur (parties aériennes de) HU (magyar): Pásztortáska virágos hajtás IT (italiano): Borsa del pastore parti aeree LT (lietuvių kalba): LV (latviešu valoda): Ganu plikstiņa laksti MT (malti): NL (nederlands): Herderstasje PL (polski): Ziele tasznika PT (português): Bolsa-de-pastor, partes aéreas RO (română): Iarbă de traista ciobanului SK (slovenčina): Vňať kapsičky pastierskej SL (slovenščina): Zel navadnega plešca SV (svenska): Lomme IS (íslenska): NO (norsk): Gjertertaske 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 77523 7051 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.

Community herbal monograph on Capsella bursa-pastoris (L.) Medikus, herba 1. Name of the medicinal product To be specified for the individual finished product. 2. Qualitative and quantitative composition 1,2 With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended Capsella bursa-pastoris (L.) Medikus, herba (shepherd s purse) i) Herbal substance Not applicable. ii) Herbal preparations a) Comminuted herbal substance b) Liquid extract (DER 1:1), extraction solvent ethanol 25% V/V 3. Pharmaceutical form Comminuted herbal substance as herbal tea for oral use. Herbal preparations in liquid dosage forms for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term. 4. Clinical particulars 4.1. Therapeutic indications Traditional herbal medicinal product for the reduction of heavy menstrual bleeding in women with regular menstrual cycles, after serious 1 The material complies with Ph. Fr. (10 e edition) as amended by supplement no 38, 1997. 2 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. EMA/HMPC/262766/2010 Page 2/5

conditions have been excluded by a medical doctor. The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use. 4.2. Posology and method of administration 3 Posology Adults Use to be started 3-5 days before the menstruation and to be continued during menstrual bleeding. a) Comminuted herbal substance: 1-5 g as a single dose for the preparation of herbal tea, 2-4 times daily (daily dose: 3-20 g). b) Liquid extract: 1-4 ml as a single dose, 3 times daily (daily dose: 3-12 ml). The use in adolescents under 18 years of age is not recommended (see section 4.4 Special warnings and precautions for use ). Duration of use If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Method of administration Oral use. 4.3. Contraindications Hypersensitivity to the active substance. 4.4. Special warnings and precautions for use The use in adolescents under 18 years of age is not recommended because of concerns requiring 3 For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC Glossary on herbal teas (EMA/HMPC/5829/2010 Rev.1). EMA/HMPC/262766/2010 Page 3/5

medical advice. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. For extracts containing ethanol, the appropriate labelling for ethanol, taken from the Guideline on excipients in the label and package leaflet of medicinal products for human use, must be included. 4.5. Interactions with other medicinal products and other forms of interaction None reported. 4.6. Fertility, pregnancy and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available. 4.7. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. 4.8. Undesirable effects None known. If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted. EMA/HMPC/262766/2010 Page 4/5

4.9. Overdose No case of overdose has been reported. 5. Pharmacological properties 5.1. Pharmacodynamic properties Directive 2001/83/EC as amended. 5.2. Pharmacokinetic properties Directive 2001/83/EC as amended. 5.3. Preclinical safety data Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed. 6. Pharmaceutical particulars Not applicable. 7. Date of compilation/last revision 12 July 2011 EMA/HMPC/262766/2010 Page 5/5